| Author (Corporate) | European Medicines Agency |
|---|---|
| Series Title | Press Release |
| Series Details | EMA/717915/2013 (22.11.13) |
| Publication Date | 22/11/2013 |
| Content Type | News |
|
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), in November 2013, recommended the authorisation of Deltyba (delamanid) and Para-aminosalicylic acid Lucane (para-aminosalicylic acid), two treatment options for use in combination with other medicines against multidrug-resistant tuberculosis. |
|
| Source Link | Link to Main Source http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/11/news_detail_001972.jsp&mid=WC0b01ac058004d5c1 |
| Related Links |
|
| Subject Categories | Health |
| Countries / Regions | Europe |
